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ORIGINAL ARTICLE
Manipulation of Lipid Metabolism During 
Normothermic Machine Perfusion: Effect 
of Defatting Therapies on Donor Liver 
Functional Recovery
Yuri L. Boteon ,1,3,4 Joseph Attard,1,3,4 Amanda P. C. S. Boteon,1 Lorraine Wallace,3,4  
Gary Reynolds,3,4 Stefan Hubscher,1,2 Darius F. Mirza,1,3,4 Hynek Mergental,1,3,4 Ricky H. Bhogal,5 
and Simon C. Afford3,4
1 Liver Unit, 2 Department of Cellular Pathology, Queen Elizabeth Hospital, and 3 National Institute for Health Research 
Birmingham Biomedical Research Centre, University Hospitals Birmingham National Health Service Foundation Trust, and 
4 Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, College of Medical and Dental 
Sciences, University of Birmingham, Birmingham, United Kingdom; and 5 The Royal Marsden, Department of Academic Surgery, 
Fulham Road, Chelsea, London
Strategies to increase the use of steatotic donor livers are required to tackle the mortality on the transplant waiting list. We 
aimed to test the efficacy of pharmacological enhancement of the lipid metabolism of human livers during ex situ normo-
thermic machine perfusion to promote defatting and improve the functional recovery of the organs. Because of steatosis, 
10 livers were discarded and were allocated either to a defatting group that had the perfusate supplemented with a combination 
of drugs to enhance lipid metabolism or to a control group that received perfusion fluid with vehicle only. Steatosis was assessed 
using tissue homogenate and histological analyses. Markers for lipid oxidation and solubilization, oxidative injury, inflammation, 
and biliary function were evaluated by enzyme-linked immunosorbent assay, immunohistochemistry, and in-gel protein detection. 
Treatment reduced tissue triglycerides by 38% and macrovesicular steatosis by 40% over 6 hours. This effect was driven by increased 
solubility of the triglycerides (P = 0.04), and mitochondrial oxidation as assessed by increased ketogenesis (P = 0.008) and adenosine 
triphosphate synthesis (P = 0.01) were associated with increased levels of the enzymes acyl-coenzyme A oxidase 1, carnitine pal-
mitoyltransferase 1A, and acetyl-coenzyme A synthetase. Concomitantly, defatted livers exhibited enhanced metabolic functional 
parameters such as urea production (P = 0.03), lower vascular resistance, lower release of alanine aminotransferase (P = 0.049), and 
higher bile production (P = 0.008) with a higher bile pH (P = 0.03). The treatment down-regulated the expression of markers for 
oxidative injury as well as activation of immune cells (CD14; CD11b) and reduced the release of inflammatory cytokines in the per-
fusate (tumor necrosis factor α; interleukin 1β). In conclusion, pharmacological enhancement of intracellular lipid metabolism dur-
ing normothermic machine perfusion decreased the lipid content of human livers within 6 hours. It also improved the intracellular 
metabolic support to the organs, leading to successful functional recovery and decreased expression of markers of reperfusion injury.
Liver Transplantation 25 1007‒1022 2019 AASLD.
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Steatosis is caused by the abnormal metabolism 
of fatty acids (FAs) in hepatocytes, resulting in 
intracytoplasmic accumulation of triacylglycerol as 
lipid droplets (LDs).(1) In the context of organ dona-
tion, livers with large intracytoplasmic LDs displacing 
the cell nucleus, ie, macrovesicular steatosis (MaS), are 
more vulnerable to ischemia/reperfusion injury (IRI) 
during standard static cold storage (SCS). This is pre-
dominantly due to impaired mitochondrial function, 
poor microcirculation, and exaggerated inflamma-
tory response leading to tissue damage.(2) The exac-
erbated IRI is then associated with impaired early 
functional recovery and a high risk of early allograft 
BOteOn et al.
Abbreviations: 4-HNE, 4-hydroxynonenal; 8-HOdG, 8-hydroxy-2-
deoxyguanosine; ACOX1, acyl-coenzyme A oxidase 1; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; ATP, adenosine 
triphosphate; AUC, area under the curve; cAMP, cyclic adenosine 
monophosphate; CAR, constitutive androstane receptor; CIT, cold 
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dysfunction.(2-4) Therefore, steatosis is one of the main 
reasons worldwide that transplant teams decline donor 
livers.(2,5)
Animal models have shown that normothermic 
machine perfusion (NMP) of the liver alone is able to 
improve intracellular lipid metabolism and promote 
steatosis reversal or defatting.(6,7) However, a recent 
study involving NMP of steatotic human livers for 
24 hours did not show a decrease in tissue steatosis.(5) 
In a murine model, a combination of drugs (peroxi-
some proliferator-activated receptor [PPAR] α ligand 
GW7647, PPARδ ligand GW501516, pregnane X 
receptor ligand hypericin, the constitutive andros-
tane receptor ligand scorparone, the cyclic adenos-
ine monophosphate [cAMP] activator forskolin, and 
the insulin-mimetic adipokine visfatin) administered 
during NMP enhanced the hepatic lipid metabolism 
and reduced tissue triglycerides (T-TGs) by 50% over 
3 hours of perfusion.(6) Similar results were observed 
with the glial cell line–derived neurotrophic factor.(8) 
However, whether those observations could be repro-
duced in human livers is still to be determined. In 
addition, the organs in these studies were not exposed 
to ischemic injury, as is the case in liver transplanta-
tion. Therefore, the defatting process in the context of 
liver transplantation remains to be determined.
We aimed to study the feasibility of the delivery 
of this combination of drugs to human donor livers 
undergoing end-ischemic NMP within the regular 
process of organ donation and cold preservation. The 
impact of this intervention on the mobilization and 
metabolization of intracellular lipids leading to defat-
ting was assessed, together with its effects on recovery 
of the metabolic activity of the organs.
Patients and Methods
stUDY Design anD sOUrce OF 
DiscarDeD DOnOr livers
Ten human livers discarded for transplantation were 
randomly allocated to the experimental groups using 
the covariate adaptive randomization method that ac-
counted for donor type and cold ischemia time (CIT). 
These were subsequently submitted to NMP for 
12  hours after variable periods of SCS. The criterion 
for inclusion of an organ in the study was a rejection 
for transplantation due to the macroscopic assessment 
of steatosis by the transplant and/or retrieval surgeon. 
If a donor biopsy was taken beforehand, the histologi-
cal grade of steatosis was recorded. However, absence of 
histological assessment of steatosis was not an exclusion 
ischemia time; CoA, coenzyme A; CPT1A, carnitine palmitoyltransferase 
form 1A; DBD, donation after brain death; DCD, donation after 
circulatory death; DMSO, dimethyl sulfoxide; ECD, extended criteria 
donor; ET, Eurotransplant; FA, fatty acid; GGT, gamma-glutamyl 
transpeptidase; H & E, hematoxylin-eosin; HA, hepatic artery; HDL, 
high-density lipoprotein; IL, interleukin; IQR, interquartile range; 
IRI, ischemia/reperfusion injury; IRS, modified immunoreactive score; 
LD, lipid droplet; MaS, macrovesicular steatosis; MiS, microvesicular 
steatosis; NHSBT, National Health Service Blood and Transplant; 
NMP, normothermic machine perfusion; PAS, periodic acid–Schiff; 
PCO2, partial pressure of carbon dioxide; PPAR, peroxisome proliferator-
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storage; TG, triglyceride; TKB, total ketone bodies; TNF-α, tumor 
necrosis factor α; T-TG, tissue triglyceride; VLDL, very low density 
lipoprotein; WIT, warm ischemia time.
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criterion in the study because donor liver biopsy is not 
routinely performed in the United Kingdom, and even 
when a biopsy was done, this information was not always 
available at the time of the inclusion of the organ in the 
study. The defatting group had the perfusion fluid sup-
plemented with a combination of drugs to improve lipid 
metabolism (defatting cocktail; 5 livers), and a control 
group (5 livers) received vehicle only in the perfusion 
fluid (dimethyl sulfoxide [DMSO] <0.01%). The com-
prehensive protocols for sampling (including core nee-
dle liver biopsy and perfusate and bile analysis) and data 
collection are presented in the Supporting Materials.
All study livers were originally retrieved with the 
intention of transplantation as per policy of the National 
Health Service Blood and Transplant (NHSBT). The 
organs were then rejected for transplantation by all UK 
centers and offered for research by the NHSBT. The 
authors had no influence in the process of declining 
donor organs, which was done by the transplant surgeon 
on call in the different transplant centers. The authori-
zation for research use of the organ is obtained by the 
specialist nurse in organ donation in accordance with 
NHSBT guidelines. Ethical approval for the study was 
obtained from the London-Surrey Borders National 
Research Ethics Service (reference 13/LO/1928) and 
the NHSBT ethics committee (reference 06/Q702/61).
liver perFUsiOn prOceDUre
After arrival at our center, the organs were prepared 
following the standard bench preparation as described 
elsewhere.(9) The cystic duct was ligated, and a 
10-Fr bile cannula was inserted in the common bile 
duct. Liver Assist (Organ Assist, Groningen, the 
Netherlands) was the device used for the perfusions 
(details are provided in the Supporting Methods). The 
perfusate consisted of 3 units of packed red blood cells, 
5% wt/vol human albumin solution, and additional 
drugs as specified in Supporting Table 1.
tHe DeFatting cOcKtail OF 
DrUgs
A previously published cocktail of drugs(6) (10  μM 
of forskolin; 1  μM of GW7647; 10  μM of hyperi-
cin; 10 μM of scoparone; 0.4 ng/mL of visfatin; 1 μM 
of GW501516) was supplemented with 0.8  mM of 
L-carnitine diluted in DMSO and added in the perfu-
sate for the defatting group when the perfusate reached 
37°C. The control group received an equal amount of 
DMSO (<0.01% vol/vol) in the perfusate within the 
same time frame. The absence of in vitro cytotoxicity 
of the combination of drugs on primary human liver 
cells has been previously published by our group.(10) 
Moreover, detailed pharmacodynamics of the defatting 
agents was recently reviewed.(11) Drugs were obtained 
from Sigma-Aldrich (St. Louis, MO), and a list is pro-
vided in the Supporting Methods.
taBle 1. Donor Demographics, liver characteristics, and 
Machine perfusion Data
Characteristic Defatting (n = 5) Control (n = 5) P Value
Donor information
Age, years 52 (47-61) 49 (44-66) 0.98
DCD livers 2 (40%) 2 (40%) >0.99
Sex, male 3 (60%) 3 (60%) >0.99
Height, cm 174 (162-184) 172 (167-184) 0.72
Body weight, kg 86 (75-100) 95 (75-105) 0.67
Body mass index, 
kg/m2
30 (28-34) 28 (25-34) 0.52
Donor risk index 2.0 (1.9-2.8) 2.0 (1.8-2.1) 0.22
UK donor liver index 1.1 (1.0-1.8) 1.3 (0.9-1.8) 0.94
ET donor risk index 1.9 (1.8-3.1) 2.0 (2.0-2.5) 0.75
Peak ALT, IU/L 66 (39-99) 104 (39-109) 0.38
Peak GGT, IU/L 110 (46-239) 355 (31-369) 0.29
Days on ventilator 2 (2-4) 3 (1-4) 0.64
Liver characteristics
Liver weight, g 1874 (1731-2362) 2130 (1775-2228) 0.93
Donor WIT, minutes 12 (10-14) 13 (13-13) 0.70
DCD CIT, minutes 774 (729-820) 770 (740-800) 0.65
DBD CIT, minutes 754 (727-788) 723 (621-729) 0.29
Machine perfusion 
parameters
Lactate, mmol/L
Start (0 hours) 11.1 (9.2-14.4) 10.6 (9.4-11.8) >0.99
Highest 11.6 (10.4-16.3) 14.7 (12.1-18.8) 0.38
Lowest 0.9 (0.3-1.8) 1.6 (0.7-11.7) 0.14
Last (12 hours) 1.9 (0.6-2.7) 2.2 (1.0-16.0) 0.003
Sodium bicarbonate 
8.4% supplementa-
tion, mL
20 (15-27) 40 (30-90) 0.04
Total bile production, 
mL/hour
1.7 (1.6-2.6) 0.6 (0.2-1.6) 0.02
Bile pH (12 hours) 7.8 (7.7-8.0) 7.3 (7.1-7.6) 0.02
Median arterial flow, 
mL/minute
360 (283-405) 286 (167-343) 0.09
Median PV flow,  
mL/minute
1316 (1232-1515) 1020 (900-1302) 0.06
Viability achievement 5 (100%) 2 (40%) 0.04
NOTE: Data are given as mean (IQR). Bolded P values are sta-
tistically significant.
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HistOlOgical evalUatiOn
Tissue biopsies were embedded in paraffin and cut 
in sections of 4 μm. Staining with hematoxylin-eosin 
(H & E) was performed to assess necrosis, grade of 
steatosis, preexisting acute or chronic liver injury, and 
periodic acid–Schiff (PAS) for glycogen stores. MaS 
was defined as the presence of a large LD filling up 
the hepatocytes and displacing the nucleus to the pe-
riphery. Microvesicular steatosis (MiS) refers to the 
presence of numerous small LDs in the hepatocytes 
(“foamy” aspect) without affecting cell nuclei position. 
MaS was graded based on the percentage of hepato-
cytes involved (none, <5%; mild, 5%-30%; moderate, 
>30%-60%; and severe, >60%). MiS was reported as 
present or absent. Histological assessment was done 
under lower magnification (magnification ×4 to ×10) 
and confirmed under higher magnification (magnifi-
cation ×20 to ×40), if required. It was conducted by 2 
independent pathologists (G.R. and S.H.) blinded to 
the study group.
assessMent OF lipiD 
MetaBOlisM
Perfusate total cholesterol, high-density lipoprotein 
(HDL), and perfusate triglycerides (P-TGs) were 
measured at the hospital clinical laboratories. T-TG 
was assessed from tissue homogenates using a com-
mercially available kit (number 10010303; Cayman 
Chemical, Miami, FL) following the manufacturer’s 
guidelines. Percentages were used to compare the 
differences in T-TG between 2 time points (the dif-
ference between levels at 6 or 12  hours and time 0, 
divided by the time 0 value, multiplied by 100). Total 
ketone bodies (3-hydroxybutyric acid and acetoacetic 
acid) were measured in the perfusate using a com-
mercial kit (MAK134; Sigma-Aldrich) following the 
manufacturer’s instructions.
In-gel fluorescent protein staining was performed 
to investigate changes across groups in the transcription 
of 3 key enzymes in the intracellular lipid metabolism:
1. Acetyl-coenzyme A (CoA) synthetase promotes 
the reaction of CoA with FAs generating the 
substrate required for mitochondrial β-oxidation 
of FAs.
2. The liver-specific 1A form of carnitine palmitoyl-
transferase form 1A (CPT1A) responsible for the 
shuttle of acetyl-CoA into the mitochondrial ma-
trix for oxidation.
3. Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), 
an essential enzyme for the peroxisomal oxidation 
of medium- to long-chain FAs.
Detailed techniques and the list of antibodies are 
provided in the Supporting Materials.
assessMent OF tHe liver 
MetaBOlisM
Parameters used in our unit as indicators of ongo-
ing liver metabolism were applied to define whether 
organs would be potentially transplantable.(12) Other 
parameters, such as the dynamics of lactate clearance, 
bile quality (assessed by bile pH), urea production, 
release of transaminases in the perfusate, and oxy-
gen uptake, were also investigated. For analysis of 
dynamic changes in lactate metabolism over time, 
the area under the curve (AUC) of lactate concen-
trations in the perfusate between 0 and 12 hours was 
analyzed. Oxygen uptake was calculated as the dif-
ference between the oxygen inf low and the outf low 
in kPa.
BiOcHeMistrY analYsis
Markers of hepatocellular injury (alanine aminotrans-
ferase [ALT] and aspartate aminotransferase [AST]), 
biliary injury/function (gamma-glutamyl transpepti-
dase [GGT]), and protein release (albumin and total 
protein) were measured in the perfusate (time points 
in the sampling protocol).
cellUlar energY statUs 
assessMent
Levels of adenosine triphosphate (ATP) were assessed 
using a f luorometric commercial kit from liver tissue 
homogenates as per the manufacturer’s recommenda-
tions (MAK190; Sigma-Aldrich). Levels were nor-
malized to mg of protein.
assessMent OF OXiDative 
inJUrY anD inFlaMMatiOn
Immunohistochemistry was performed on formalin- 
fixed, paraffin-embedded sections for the expression 
of the marker of cell membrane phospholipid perox-
idation 4-hydroxynonenal (4-HNE). To assess tissue 
inflammation, CD11b, an integrin on the surface of 
activated leukocytes, and CD14, a lipopolysaccharide 
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receptor that is part of the toll-like receptor 4 signalo-
some and participates in the development of the IRI, 
were investigated. For the detailed technique and an-
tibodies list, refer to Supporting Methods. Staining 
expression was scored using a semiquantitative scoring 
system, the modified immunoreactive score (IRS).(13) 
This takes into consideration intensity of staining 
(0, no color reaction; 1, mild reaction; 2, moderate 
reaction; and 3, intense reaction) and its distribution 
(0, no positive cells; 1, <10% positive cells; 2, 10%-50% 
positive cells; 3, 51%-80% positive cells; and 4, >80% 
positive cells). A final score between 0 and 12 is 
obtained by multiplying the 2 parameters.
Perfusate tumor necrosis factor α (TNF-α), inter-
leukin (IL) 10, and IL1β levels were determined 
using sandwich enzyme-linked immunosorbent assay 
(RAB0476, RAB0244, RAB0273; Sigma-Aldrich); 
8-hydroxy-2-deoxyguanosine (8-HOdG) was assessed 
in the perfusate using a commercially available kit 
(ab201734; Abcam, Cambridge, MA) following the 
manufacturer’s instructions. All samples were tested in 
duplicate.
statistical analYsis
Continuous variables were expressed as median with 
interquartile range (IQR) and categorical variables 
as an absolute number with percentage frequencies. 
Comparisons between groups were performed using 
2-tailed Fisher’s exact test for categorical variables, 
Mann-Whitney U test or Student t test for indepen-
dent continuous variables, and Wilcoxon signed-rank 
test for repeated measurements over time on the same 
sample. Correlations between variables were analyzed 
using Pearson’s correlation coefficient. The AUC was 
calculated using the trapezoidal rule. The statistical 
level of significance was set at P  <  0.05. GraphPad 
Prism, version 6.04 (GraphPad Software, La Jolla, 
CA) software was used for all statistical analyses and 
graph creation.
Results
DOnOr DeMOgrapHics anD 
perFUsiOn paraMeters
Overall median donor age was 51  years (IQR, 
47-58 years), median donor risk index was 2.0 (2.0-2.1), 
and median CIT was 737 minutes (717-805 minutes). 
Each study group included 3 donation after brain death 
(DBD) and 2 donation after circulatory death (DCD) 
livers. The groups were comparable in terms of donor 
characteristics and preservation times. Details are pro-
vided in Table 1 and Supporting Table 2.
Treated livers developed higher median portal vein 
(PV) flows (P = 0.06) with lower vascular resistance 
(P = 0.005) from the start until 12 hours of perfusion. 
There was a trend of higher median hepatic artery 
(HA) flows in the defatting group (P = 0.09) with a 
significantly lower HA resistance (P = 0.003) during 
this period. There was a strong correlation between 
T-TG and flows at times 6 and 12 hours on the HA 
(r = –0.66, P = 0.04 and r = –0.68, P = 0.03, respec-
tively) and PV (r = –0.79, P = 0.007 and r = –0.81, 
P = 0.004, respectively). Vascular parameters of the 
livers during perfusion are shown in Fig. 1.
liver parencHYMa HistOlOgY
Each experimental group initially had 1 liver histolog-
ically classified as severely steatotic, 2 as moderately 
steatotic, 1 as mildly steatotic, and 1 as nonsteatotic. 
Changes between categories throughout the perfusion 
and the presence of MiS are presented in Tables 2 and 
3. Positive PAS staining of parenchymal areas was con-
stant along the perfusion for the control group, whereas 
the defatting group presented with a trend of increase 
mainly during the initial 6 hours of perfusion (Fig. 2).
lipiD MetaBOlisM 
MODUlatiOn anD DeFatting
The levels of T-TG dropped by 38% (23%-51%) in the 
defatting group and 7% (3%-10%) in the control group 
over 6 hours (P = 0.003), and 30% (21%-35%) in the 
defatting group versus 10% (6%-13%) in the control 
group over 12 hours (P = 0.002), in comparison with 
time 0. MaS rate of defatted livers decreased by 40% 
(17%-50%) over 6  hours and 50% (15%-60%) over 
12 hours; there were no changes in the control group 
(P = 0.02 and P = 0.005, respectively; Fig. 2; Table 3).
Ketogenesis was enhanced in the defatting group until 
6 hours (P = 0.008). ATP levels were similar at time 0 
and then increased significantly until 6 hours of perfu-
sion for the defatting group and decreased for the control 
group (P = 0.01 and P = 0.008, respectively; Fig. 3).
Median P-TG fell over the first 2 hours. Following 
this, it increased significantly until 6 hours in the defat-
ting group (P = 0.04) but not in the control (P = 0.59). 
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The increase in P-TG levels showed a correlation with 
the drop in T-TG between time points 0 to 6 hours 
(r = –0.58; P = 0.08) and 0 to 12 hours (r = –0.59; 
P = 0.07). There was no correlation between median 
P-TG levels and ALT concentrations in the perfusate 
(r = 0.18; P = 0.65).
The levels of total cholesterol followed the same 
pattern and were higher in the defatting group at 6 
(P =  0.02) and 12 hours of perfusion (P =  0.003). 
HDL cholesterol was below the limit of detection of 
the laboratory until 6 hours of perfusion (1.9 mg/dL) 
and started to increase thereafter; however, it did 
not achieve a statistically significant difference at 
12  hours of perfusion (P  =  0.28). Protein in-gel 
staining revealed that defatted livers had at 6-hour 
perfusion a 3.0-fold increase in the protein levels 
of acetyl-CoA synthetase, 1.4-fold in ACOX1, and 
6.0-fold in CPT1A (Fig. 3).
liver viaBilitY, 
HepatOcellUlar MetaBOlic 
FUnctiOnal paraMeters,  
anD BiOMarKers
Lactate levels were comparable at time 0, and then 
they decreased significantly until 12  hours of per-
fusion in the treatment group but not in the control 
group (P = 0.04 and P = 0.22, respectively). Dynamic 
changes in the lactate metabolism, as assessed by the 
AUC, showed that, considering both groups, smaller 
Fig. 1. Perfusion parameters. (A-F) The vascular parameters of the livers during perfusion. (A) The PV f low rate was higher in the 
defatted livers throughout the perfusion in comparison with the control group, (B) which was associated with a faster decrease in 
vascular resistance. There was a strong negative correlation between T-TG levels and vascular f lows at 12 hours on the (C) PV and 
(F) HA. (D) The HA f low rate with trends toward higher values for the defatting group, (E) which is potentially associated with 
the faster decrease in HA vascular resistance at the beginning of perfusion. (G-I) Metabolic parameters of the livers during machine 
perfusion. (G) Perfusate urea concentration increased significantly more in the defatting group in comparison with the control group, 
which also had a rising trend. (H) Defatted livers metabolized perfusate lactate more effectively than the control group, reaching lower 
median concentrations. (I) Glucose levels peaked during the initial 2 hours of perfusion and then decreased steadily. In the control 
group, figures were stable initially and then tended to increase toward the end of the perfusion period. (J-L) Data from biliary function 
and injury. (J) GGT levels in the perfusate increased significantly more in the control group. Concomitantly, treated livers produced 
significantly (K) more bile throughout the perfusion (L) with a higher bile pH. In all panels, the dots represent individual organs at 
the time points listed and the line indicates the median of the values for each group. Comparisons between groups were made with the 
Mann-Whitney U test. r = Pearson’s correlation coefficient. *Statistical significance at P < 0.05.
taBle 2. steatosis assessment analysis
Case Donor Type CIT, minutes
MaS* MiS
Time 0 Time 6 Time 12 Time 0 Time 6 Time 12
Defatting Group
1 DBD 823 Moderate Moderate Mild Present Present Present
2 DCD 729 Moderate Moderate Mild Present Present Present
3 DBD 700 Mild None None Present Present Present
4 DBD 754 Severe Moderate Moderate Present Present Present
5 DCD 820 None None None Present Present Present
Control Group
1 DBD 520 Mild Mild Mild Present Present Present
2 DCD 740 Moderate Moderate Moderate Present Present Present
3 DCD 800 None None None Present Present Present
4 DBD 723 Severe Severe Severe Absent Absent Absent
5 DBD 735 Moderate Moderate Moderate Present Present Present
*The severity of MaS was assessed in accordance with the parenchymal hepatocytes that had fatty changes: none, <5%; mild, 5%-30%; 
moderate, >30%-60%; and severe, >60%. These are the results of MaS assessment on H & E–stained definitive paraffin sections, 
performed by 2 independent pathologists at our center blinded to the study’s groups, using the parameters specified in the Patients and 
Methods section. Results from frozen sections evaluated externally for clinical purposes are available in Supporting Table 2 and were 
not included in the study’s analysis.
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lactate AUC was associated with higher total perfusion 
f lows (r = –0.84; P = 0.002), increased urea produc-
tion (r = –0.73; P = 0.02), higher bile pH at 6 hours 
(r  =  –0.88; P  =  0.02), increased release of P-TG 
(r  =  –0.90; P  <  0.001), lower expression of 4-HNE 
(r = 0.62; P = 0.05), and a trend for higher bile pro-
duction (r  =  –0.58; P  =  0.08). The defatting group 
demonstrated a trend of shorter time to peak lactate 
and time to achieve lactate <2.5 mmol/L, which were 
correlated with positive metabolic factors. Further de-
tails are provided in Supporting Fig. 1.
All treated livers reached our viability criteria and 
therefore would be considered transplantable based 
solely upon these criteria. From the control group, only 
2 organs recovered functional parameters that would 
be considered transplantable (P = 0.04). Achievements 
of the parameters of the criteria are presented in 
Supporting Table 3.
Defatted livers produced more urea over the ini-
tial 6 hours (P =  0.03). There was a strong negative 
correlation between lactate and urea levels at 6 hours 
(r  =  –0.82; P  =  0.004) and 12  hours (r  =  –0.77; 
P  =  0.009). Increased P-TG correlated with an 
increased production of urea at 6  hours (r  =  0.87; 
P = 0.001) and 12 hours (r = 0.63; P = 0.05). Median 
perfusate glucose increased from time 0 to 2  hours 
in the defatting group (P = 0.10) and then decreased 
toward 12  hours (P  =  0.08). Those levels were con-
stant for the control group. Metabolic parameters of 
the livers are presented in Fig. 1. Electrolytes and other 
biochemistry parameters are presented in Supporting 
Fig. 2.
The viable livers from the control group released 
less median (IQR) total cholesterol (17.4 [15.5-19.3] 
versus 30.9 [23.2-38.7] mg/dL; P = 0.02) and P-TG 
(110.7 [88.6-132.9] versus 177.1 [177.1-186.0] mg/dL; 
P = 0.048) at 12 hours and produced less ATP (400 
[390-410] versus 1417 [1138-1453] pmol/mg; P = 0.03) 
and developed a higher expression of 4-HNE (IRS, 2 
[2-2] versus 1 [1-1]; P = 0.02) at 6 hours in compari-
son with defatted livers.
BiliarY inJUrY anD FUnctiOn
Cumulative bile production was higher for the defat-
ting group at the 6-hour (P = 0.03) and 12-hour perfu-
sion time points (P = 0.008). There was no statistically 
significant correlation between total cholesterol in the 
perfusate and cumulative bile production at 6  hours 
(r = 0.59; P = 0.07) or 12 hours of NMP (r = 0.59; 
P = 0.07).
Bile quality, as assessed by the bile pH measured at 
12 hours, was also higher in the defatting group (7.8 
[7.7-8.0] versus 7.3 [7.1-7.6]; P = 0.03). GGT levels 
in the perfusate increased significantly from time 0 to 
12 hours of perfusion in the control group (P = 0.04). 
Details are presented in Fig. 1.
HepatOcellUlar inJUrY, 
OXiDative DaMage, anD 
activatiOn OF iMMUne cells
Perfusate ALT levels were lower in the defatted livers 
at 12 hours of perfusion (P = 0.049; Fig. 4). Perfusate 
8-HOdG levels were similar at the 6-hour time 
point followed by a general increase until 12 hours in 
the control group and a stabilization of levels in the 
defatting group (P  =  0.10). Immunohistochemical 
analysis for 4-HNE demonstrated similar initial 
levels at the beginning of the perfusion followed 
by an increase in the control group and a decrease 
in the defatting group at 6 hours (P = 0.02). There 
was a strong negative correlation between P-TG and 
4-HNE expression (r = –0.87; P = 0.001) at 6 hours 
of perfusion.
The activation of the Kupffer cells and neutrophils 
in liver tissue, as assessed by immunohistochemical 
taBle 3. steatosis rates variation analysis
Parameter Defatting (n = 5) Control (n = 5) P Value
T-TGs analysis
T-TG, mg/g of liver
Time 0 2.7 (1.9-3.5) 3.3 (1.9-3.7) 0.84
Time 6 1.6 (0.9-2.6) 3.2 (1.7-3.6) 0.03
Time 12 2.0 (1.2-2.6) 3.1 (1.6-3.4) 0.02
ΔT-TG, %
Time 0 to 6 38 (23-51) 7 (3-10) 0.003
Time 0 to 12 30 (21-35) 10 (6-13) 0.002
Histological assessment analysis, %
MaS
Time 0 31 (10-58) 40 (7-65) 0.82
Time 6 15 (5-35) 30 (7-65) 0.31
Time 12 15 (5-22) 40 (7-65) 0.13
ΔMas
Time 0 to 6 40 (17-50) 0 (0-12) 0.02
Time 0 to 12 50 (15-60) 0 (0-12) 0.005
NOTE: Bolded P values are statistically significant. ΔT-TG and 
ΔMaS are related to the variation in the figures between begin-
ning and end of the period divided by the beginning.
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analysis (CD14 and CD11b, respectively), was similar 
between groups at time 0, and then, it increased for 
the control group, reaching higher scores at 12 hours 
(P = 0.046 and P = 0.045, respectively). The cytokine 
profile showed a decrease in the perfusate levels of the 
inflammatory TNF-α from time 0 to 6, and from 0 to 
12 hours in the defatting group. IL1β also decreased 
over the course of the perfusions in the treatment 
group. For both markers, the levels in the control were 
either flat or increased. The anti-inflammatory IL10 
increased in both groups from the beginning until a 
time of 6  hours, and then, it decreased faster in the 
defatting group (Fig. 4).
Of note, similar enhancement in the lipid metabo-
lism leading to a decrease in T-TG, via increased oxi-
dation of FAs and solubilization in the perfusate, along 
with improved biliary function and lower hepatocellu-
lar injury, was seen in a subanalysis of organs deemed 
Fig. 2. T-TGs content and histological steatosis assessment analysis. (A) Homogenate T-TGs were comparable at time 0 and then 
decreased over 6 and 12 hours of perfusion in the defatting group, reaching lower levels than the control group. The bar represents 
the median and error bars the IQR. (B) At the histological assessment of MaS on H & E staining, a similar trend was observed. 
(C) Defatted livers were more depleted of glycogen at time 0. However, their levels increased, already surpassing the control group 
at 6 hours of perfusion. The areas positive for PAS were constant for the control group throughout the perfusion. The dots represent 
individual organs at the time points listed and the line indicates the median of the values for each group. (D) An image from a histologically 
moderately steatotic liver that received the defatting cocktail and (E) presented with a significant reduction in macrovesicular steatosis 
already at 6 hours of perfusion. (G) The presence of MiS in the same liver at time 0 is seen, (H) as is the change at 6 hours. (F) An image 
from a mildly steatotic liver from the defatting group with an important depletion of glycogen stores, (I) replenishing its stores over 
6 hours of perfusion. Comparisons between groups were made with the Mann-Whitney U test. *Statistical significance at P < 0.05.
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mildly steatotic and nonsteatotic on histology. Results 
are presented in Supporting Table 4.
Discussion
Steatosis has become the leading reason for surgeons to 
decline donor livers for transplantation, which, in turn, 
is worsening the growing discrepancy between organ 
availability and the increasing number of patients on 
transplant waiting lists.(14,15) We have shown that 
the delivery of a pharmacological intervention during 
NMP was able to decrease the fat content of whole 
human livers within 6 hours. This effect was driven 
by enhanced lipid metabolism, as increased oxidation 
of lipids and exportation to the perfusate. Importantly, 
this enhanced lipid metabolism increased the meta-
bolic support to the organ, improving its functional re-
covery. It was associated with enhanced mitochondrial 
functioning, decreased vascular resistances, and re-
duced markers of hepatocellular injury and inflamma-
tion with improved biliary function. These parameters 
are suggested as being indicative of transplantability 
for extended criteria donor (ECD) organs undergoing 
NMP, according to the evidence available to date.(16,17) 
Therefore, manipulation of the hepatic lipid metabo-
lism during NMP may defat steatotic organs and in-
crease their functional recovery, potentially halting the 
harmful effects of reperfusion injury.
Previous in vitro studies with fat-laden rat hepato-
cytes and hepatoblastoma cells demonstrated the fea-
sibility of defatting cells with a combination of drugs 
over 48 hours.(6,18,19) Thereafter, this defatting cocktail 
was delivered to whole steatotic rat livers during NMP, 
and the authors demonstrated a decrease in T-TG 
of 50% within 3 hours.(6) Interestingly, a decrease of 
30% could be obtained with NMP alone over the same 
period.(6) However, a recent study reporting results of 
24 hours of perfusion of steatotic human livers could 
not replicate the same results with NMP alone.(5) This 
raised concerns about variability in response between 
species and about how the effectiveness of the drugs 
could be compromised after the inherent ischemic 
injury that follows organ retrieval.
A description of the detailed pharmacological 
effects of the drugs used is out of the scope of this 
manuscript, but the effects of the drugs have recently 
been reviewed.(11) The evidence for the safety of 
the individual components of the defatting agents 
is presented in Supporting Table 5. Although the 
authors believe that there is solid evidence support-
ing the safety of using all of the suggested drugs 
during NMP, there is a lack of clinical markers for 
some of the compounds; thus, a selection of those 
drugs undergoing clinical trials may be an option. 
Our group recently reported, for the first time, the in 
vitro effectiveness of these pharmacological agents in 
defatting primary human hepatocytes that were made 
fatty by supplementation with FAs.(10) Apart from 
being nontoxic to these cells, the defatting process 
decreased intracellular hepatocyte triglycerides (TG) 
by 35% over 48  hours of incubation. These agents 
were also shown for the first time to not be toxic to 
nonparenchymal liver cells (intrahepatic endothelial 
cells and cholangiocytes).(10)
In this study, we delivered the defatting cocktail to 
human donor livers exposed to extended periods of 
CIT. We have found that NMP supplemented with 
the defatting cocktail improves lipid metabolism, sig-
nificantly decreasing T-TG by 38% over a period of 
6 hours, whereas NMP alone reduced it by 7% over the 
same time. Histologically, it corresponded to a decrease 
of 40% in MaS rate in the defatting group and there 
was no change in the control group. This defatting 
effect was associated with an enhanced mitochondrial 
function (β-oxidation of FAs, mitochondrial respira-
tion [higher oxygen uptake], ketogenesis, augmented 
urea cycle, and Krebs cycle activity with higher ATP 
Fig. 3. Metabolic pathways for elimination of intracellular TGs. (A-D) Enhanced mitochondrial oxidation of FAs results in (A) 
increased ketogenesis throughout the perfusion. However, it was more pronounced in the treatment group. (B) Mitochondrial respiration 
assessed by PCO2 production increased steadily for both experimental groups, and (C) the oxygen uptake was higher for the initial 3 hours in the defatting group and then decreased slightly. (D) This change was associated with increased ATP replenishing within 
the initial 6 hours in the defatting group and then decreased steadily, maintaining higher concentrations than the control group. (E-G) 
In addition, there was an increase in exportation of FAs. (E) The levels of total cholesterol in the perfusate increased faster in defatted 
livers than did the (F) levels of TGs. (G) HDL cholesterol levels were below the detection range and started to increase slowly after 
6 hours of perfusion. (H,I) In-gel f luorescent protein stain normalized to the total protein was performed for acetyl-CoA synthetase, 
CPT1A, and peroxisomal ACOX1. Experiments were performed (n = 5), and (H) representative figures are presented. (I) The peak 
of intensity in densitometric analysis at the specific protein band was compared between the groups. In all panels, the dots represent 
individual organs at the time points listed and the line indicates the median of the values for each group. Comparisons between groups 
were made with the Mann-Whitney U test. *Statistical significance at P < 0.05.
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synthesis) and increased exportation of intracellular 
TGs as lipoproteins in the perfusate. Mechanistically, 
it was represented by up-regulation in the levels of key 
enzymes involved in intracellular lipid metabolism in 
comparison with control livers. Beneficial effects were 
also seen in glucose metabolism, where defatted livers 
released more glucose in the perfusate during the initial 
hours of perfusion. This enhanced gluconeogenesis is 
likely to be related to an increased availability of glyc-
erol because of the augmented breakdown of lipids with 
higher production of glucose-6-phosphate. Glucose-6-
phosphate, in turn, will generate the glucose released in 
the perfusate and activate the enzyme glycogen synthase 
promoting glycogenesis, in accordance with our find-
ings.(20) A diagrammatic summary is provided in Fig. 5.
In addition, modulation of the lipid metabolism 
halted hepatocellular injury as assessed by the dimin-
ished release of ALT in the perfusate. Tissue damage 
during reperfusion is primarily related to mitochondrial 
dysfunction with reactive oxygen species (ROS) pro-
duction, oxidative stress, and a concomitant proinflam-
matory response. Accordingly, treated livers developed 
lower cellular DNA damage (8-HOdG) by the end of 
the perfusion as well as lower rates of lipid peroxida-
tion (4-HNE), production of inflammatory cytokines, 
and activation of immune cells (CD14, CD11b). The 
former could also have resulted from the direct effects 
of the defatting constituents, such as PPARs.(21,22) 
Our findings corroborate those of previous in vitro 
studies, in which delivering the cocktail to fat-laden 
rat hepatocytes diminished ROS concentration and 
cellular injury, as assessed by the cytosolic lactate dehy-
drogenase release into media.(18)
Ischemic cholangiopathy following DCD liver 
transplantation is of great clinical concern, and identi-
fication of high-risk donor organs during NMP, prior 
to transplantation, would be a useful clinical tool.(23) 
Watson et al. described how bile pH <7.5 during NMP 
is suggestive of biliary tree necrosis and can increase 
the risk of ischemic cholangiopathy after transplanta-
tion.(17) Contrary to this finding, treated livers demon-
strated bile pH levels higher than 7.5, whereas the 
converse was seen in control livers. Importantly, no 
correlation was found between greater bile production 
and the increase in total cholesterol in the perfusate, 
suggesting a beneficial effect of the cocktail itself on 
the biliary system. The mechanism involved needs 
further investigation. However, the protective role of 
defatting in lowering oxidative injury and tissue dam-
age can be potentially correlated.
In accordance with in vitro studies in which hepato-
cyte viability improved, the defatting cocktail used in 
this study enhanced the functional recovery of donor 
livers during NMP.(18,24,25) Urea is produced by the 
liver and results from an enzymatic reaction involving 
carbon dioxide and the ammonia derived from the 
deamination of proteins in the liver. The increased 
level of urea suggests increased urea synthesis in 
defatted livers.(19,26) Our previously published via-
bility criteria assert that lactate levels <2.5 mmol/L 
within 4 hours is a major criterion for safe transplan-
tation of ECD donor livers. However, it also consid-
ers other parameters of liver metabolism.(12,16) We 
have performed a separate analysis of the dynamic 
changes in lactate concentration over time. It showed 
a strong correlation between lactate metabolism 
kinetics (lower AUC, shorter time to peak lactate and 
the clearance from peak to 2.5  mmol/L) and other 
parameters of appropriate liver metabolism. These 
findings reinforce the significance of this marker in 
the context of defatting. The Cambridge group has 
advocated the use of transaminases, bile produc-
tion, and bile quality as appropriate markers of organ 
viability.(17) The discussion about optimal viability 
Fig. 4. Assessment of hepatocellular and oxidative injury and activation of the immune cells. (A) ALT levels released in the perfusate 
were investigated as a marker of hepatocellular injury. Levels f lattened along the perfusion in the defatting group and reached higher 
figures in the control group. (B) AST levels followed a similar trend. Markers of oxidative injury were also explored. (C) Nuclear cell 
damage assessed by 8-HOdG released in the perfusate showed stable levels in the defatting group and a trend to increase in the control 
group. (D-F) The cytokine profile was investigated, and perfusate concentration of the proinflammatory cytokines (D) TNF-α and 
(E) IL1β decreased along the perfusion in the defatting group and increased in the control group. (F) The anti-inflammatory IL10 
increased in both groups at 6 hours and then it decreased faster in the defatted livers. Immunohistochemical analysis was performed for 
markers of oxidative injury and activation of an inf lammatory response. (G) A moderate reaction of the staining committing 10%-50% 
of the hepatocytes as assessed by the IRS. (H) After 6 hours of defatting, a predominantly mild staining reaction in 10%-50% of the 
hepatocytes is seen. (I) The trends for each experimental group along the perfusion are presented. Similarly, tissue expression of (J,K) 
CD14 and (M,N) CD11b for the defatting group decreased from a time of 0 to a time of 6 hours of perfusion. (L) The changes over 
time for CD14 are indicated as are (O) the changes in tissue expression of CD11b. Scales are provided on the bottom of each panel. In 
all panels, the dots represent individual organs at the time points listed and the line indicates the median of the values for each group. 
Comparisons between groups were made with the Mann-Whitney U test. *Statistical significance at P < 0.05.
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criteria during NMP is out of the scope of this paper, 
and another topic for discussion is whether the same 
criteria or machine perfusion technique is applicable 
for all organs (eg, DBD, DCD, or defatted livers). 
However, defatted livers fulfilled all those criteria that 
are currently considered indicative of adequate liver 
metabolism and, hence, would potentially be deemed 
transplantable.
The results obtained from employing our study pro-
tocol have shown that pharmacological targeting of 
lipid metabolism can defat steatotic human livers and 
improve their metabolic function within the relatively 
short time frame of 6 hours. Beyond this time point, 
all of the benefits observed with the defatting proto-
col appeared to be sustained. This observation suggests 
that the drugs had already been metabolized at the 
Fig. 5. A suggested relationship between the defatting cocktail and intracellular lipolytic metabolic pathways. Forskolin activates 
the glucagon membrane receptors, which in turn stimulate the cAMP–protein kinase A pathway; thus, the cytoplasmic lipases are 
attracted to the surface of LDs. Glycerol and FFAs will then be released, serving not only as substrates for the cell metabolism but 
also as ligands to nuclear receptors (PPAR and liver X receptor), increasing the transcription of enzymes involved in the catabolism of 
FFAs in the mitochondria and peroxisome. Diverse cocktail drugs (GW7647, GW501516, hypericin, scorparone) also act as ligands to 
other nuclear receptors (PXRs and CARs), boosting the transcription of key enzymes. Cytosolic FA reacts with ATP, producing fatty 
acyl-CoA. Acyl-CoA in turn reacts with apolipoprotein B to generate lipoproteins to be exported from the cell and/or reacts with the 
hydroxyl group of carnitine via carnitine palmitoyltransferase I. Acyl-carnitine is transported inside the mitochondria by a carnitine-
acyl-CoA transferase, and a carnitine is transferred outside. Acyl-CoA is processed by β-oxidation. The acetyl-CoA produced then 
will follow to ketogenesis or for complete oxidation via the Krebs cycle and the electron transport chain with the production of ATP. 
Increased production of aspartate and CO2 stimulate the urea cycle, increasing the production of urea. Alternatively, long chain and very long chain FFAs are also oxidized in the peroxisomes. Glycerol is a gluconeogenic precursor; it is converted to pyruvate, producing 
glucose-6-phosphate through the gluconeogenesis pathway. Glucose-6-phosphate will be released as glucose in the perfusate and 
stimulate the enzyme glycogen synthase, increasing the production of glycogen. The squares contain the specific enzymes that have 
an up-regulation in the transcription as a consequence of this stimulus. Drugs and supplement used in the cocktail are presented in 
yellow squares.
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6-hour perfusion mark. At this point, either a second 
bolus of the cocktail could be considered to amplify its 
effects or the aim would be considered achieved and 
the organ could potentially be used for transplanta-
tion. Another point of discussion is the use of filters 
to remove solubilized lipids from the perfusate or even 
changing the perfusate, the intent of which is to poten-
tially prevent lipotoxicity. However, in the context of 
NMP and defatting, we have not seen toxic effects 
of the FAs in organ functioning, tissue damage, or 
inflammatory response. Further studies will be needed 
to investigate its potential advantages.
Banan et al.(27) showed a reduction of 10% in MaS 
over 8 hours of NMP for a discarded steatotic donor 
human liver with 80% MaS and a negligible reduction 
for a liver with 30% MaS, supplementing the perfusate 
with 10 mM of L-carnitine. However, the variability 
between the 2 reported organs and the lack of a con-
trol group limits the interpretation of the results of this 
study. This is the first study designed specifically to 
deliver a defatting cocktail of drugs to steatotic human 
livers during NMP and to assess its impact on lipid 
metabolism. Importantly, all of these observations 
were made within a scenario of clinical organ donation 
encompassing livers originating from different donors 
(DCD and DBD) exposed to extended periods of CIT 
before receiving treatment. Moreover, it is important 
to highlight that all of these benefits were also seen 
for organs deemed mildly steatotic and nonsteatotic 
on histology that had MiS. This was demonstrated 
through a decrease in their levels of T-TG along with 
the improved metabolic function and lower release of 
markers of hepatocellular injury.
Although our study has shown that ex situ phar-
macological modulation of lipid metabolism of donor 
human livers enhances its function, we have not proven 
that the livers are transplantable. This concept clearly 
demands a pilot study to assess the defatting protocol 
in clinical transplantation. In the United Kingdom, 
histological assessment of donor liver steatosis is not 
performed routinely, and livers are discarded solely 
based on a surgical macroscopic assessment of ste-
atosis. As a consequence, our groups included organs 
with various grades of steatosis, which was assessed 
at the histological level, with 2 livers having <5% 
MaS. However, they were equally distributed between 
groups. Of note, from the 3 livers deemed severely 
steatotic on a frozen section at an external center, 2 
of them had no MaS on definitive paraffin section-
ing. This discrepancy may be due to sampling issues, 
tissue preparation, or inconsistency in the assess-
ment between pathologists. To prevent bias, all of 
the study’s analyses were performed with results from 
definitive paraffin sections that were assessed blindly 
by 2 pathologists at our center, applying the standard-
ized criteria presented in the Patients and Methods 
section. Moreover, despite controlling for the donor 
type, CIT, and livers with similar degrees of steatosis, 
some other unfavorable factors were more predomi-
nant in the control group (higher GGT peak, higher 
liver weight, the oldest donor in the cohort), and the 
causes of death were not perfectly matched within 
donor type categories. Small differences between 
groups are an intrinsic limitation of research with dis-
carded human livers; however, the use of human livers 
in research has the advantage of eliminating variabil-
ity between species, the latter being a limitation of 
animal model studies. All livers had prolonged CIT, 
which, together with steatosis and other donor fac-
tors, explains the poor rescue of control livers based 
on metabolic parameters.
In addition, although we were unable to control the 
groups for the causes of hepatic steatosis—that would 
be based on the history of alcohol intake and the pres-
ence of risk factors for metabolic syndrome, such as 
diabetes mellitus and obesity—we believe this mimics 
real life. This is because the coexistence of these factors 
in the same donor makes it difficult to define a precise 
etiology at the time of the offer of a steatotic donor liver 
for transplantation. Mechanistically, the drugs increase 
the intracellular lipolysis via the cAMP–protein kinase 
A pathway and induce the transcription of enzymes 
involved in FAs catabolism in the mitochondria and 
peroxisomes, independently of insulin receptors. Thus, 
either the occurrence of insulin resistance, the hallmark 
of nonalcoholic fatty liver disease, or its absence should 
not affect the process.
In conclusion, we have shown that pharmacological 
modulation of lipid metabolism during NMP can pro-
mote defatting of whole human steatotic livers within 
6 hours. More importantly, the enhanced lipid metab-
olism improved the metabolic status of the organs and 
their functional recovery, decreased vascular resistance, 
and reduced the expression of markers of reperfusion 
injury. Those findings support further clinical inves-
tigations and open a window of opportunity for better 
use of steatotic donor livers.
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